Coronavirus Vaccine Trial Shows Positive Results

Headline Roundup May 18th, 2020

Moderna Inc., a biotech company based in Massachusetts, is reporting positive interim data in the first phase of a COVID-19 coronavirus vaccine trial, as immune responses are similar to that in people who had recovered from the disease.

The company is about to begin a phase two trial and hopes to start a phase three trial in July.

Coronavirus Vaccine Trial Shows Positive Results

From the Right
13320
coronavirus, coronavirus vaccine, Moderna, early-stage trial, antibodies, public health

Moderna Inc. said on Monday its experimental COVID-19 vaccine showed promise in a small early-stage trial, with the vaccine producing virus-neutralizing antibodies similar to that found in recovered patients.

The news sent Moderna shares (MRNA) soaring 25%.

The company's vaccine is at the forefront of the efforts in developing a treatment for the fast-spreading virus and last week, won the U.S. health agency's "fast track" label to speed up the regulatory review. Moderna expects to start a larger late-stage trial in July.

There are currently no approved treatment or vaccine...

Read full story
From the Center
13320

The biotech company Moderna on Monday reported “positive” data on its potential coronavirus vaccine from an early clinical trial, raising hopes about the effort.

The company said early data from a phase one clinical trial showed that people given the potential vaccine generated an immune response similar to that in people who had recovered from the disease.

The levels of neutralizing antibodies were “at or above” the levels seen in blood samples from people who have recovered from the coronavirus, Moderna said in a statement.

Still, that early result is...

Read full story
From the Left
13320
coronavirus, coronavirus vaccine, Moderna, early-stage trial, antibodies, public health

Moderna, the Massachusetts biotechnology company behind a leading effort to create a coronavirus vaccine, announced promising early results from its first human safety tests Monday. The company plans to launch a large clinical trial in July aimed at showing whether the vaccine works.

The company reported that in eight patients who had been followed for a month and a half, the vaccine at low and medium doses triggered blood levels of virus-fighting antibodies that were similar or greater than those found in patients who recovered. That would suggest, but doesn’t...

Read full story